Addition of vandetanib improves progression-free survival in patients with the most common form of lung cancer

June 04, 2010

Vandetanib given in addition to a standard chemotherapy regimen of docetaxel prolongs progression-free survival (PFS) and improves response rates compared with standard chemotherapy alone in patients with previously treated advanced non-small-cell lung cancer (NSCLC). These findings are the first to show significant evidence of an additional benefit when an oral targeted agent is combined with standard chemotherapy for lung cancer, according to an Article published Online First in The Lancet Oncology.

NSCLC accounts for about 85% of lung cancer cases, and is the leading cause of cancer death worldwide. The drug vandetanib is designed to target two receptors that play a key role in the growth and spread of NSCLC--epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). A previous phase 2 trial has shown that vandetanib has promising antitumour activity and increases PFS in previously treated patients with advanced NSCLC.

To further evaluate the potential of vandetanib as a treatment for advanced NSCLC, Roy S Herbst from the University of Texas MD Anderson Cancer Center, USA, and international colleagues established the phase 3 ZODIAC trial. 1391 patients who had previously received chemotherapy were recruited from 25 countries between May, 2006, and April, 2008. Patients were randomly assigned to vandetanib plus docetaxel (694) or placebo plus docetaxel (697) and followed up for an average of 12.8 months.

Overall, patients in the vandetanib group had significantly longer PFS (4.0 months) compared to the placebo group (3.2 months). While there was no significant difference in overall survival between the groups, the objective response rate* was significantly higher in the vandetanib group (17% vs 10%). Additionally, vandetanib treatment was associated with a significant improvement in time to worsening of symptoms (3.5 months vs 2.7 months).

The safety profile seen in this study is similar to that shown in other vandetanib studies. The most common side-effects found in patients in the combination group compared to placebo were diarrhoea (42% vs 33%), rash (42% vs 24%), and neutropenia (32% vs 27%). Interestingly, patients receiving vandetanib experienced a lower rate of nausea (23% vs 32%), vomiting (16% vs 21%), and anaemia (10% vs 15%).

The authors comment: "Adding vandetanib to docetaxel in patients with previously treated advanced NSCLC can slow disease progression and this is associated with better control of the symptoms caused by lung cancer...[and] raises the possibility that patients with this advanced disease can live with fewer symptoms (and consequently fewer interventions) for a longer period of time...leading to an important palliative benefit."
Professor Roy S Herbst, University of Texas MD Anderson Cancer Center, Houston, USA. T) +1 713 705 6689 (mobile) E)


Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to